Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Novel FTase inhibitors prepared and tested at Janssen

Oct. 31, 2003

Recombinant human angiostatin well tolerated in cancer patients

Oct. 31, 2003

Acceptable safety profile described for oral diflomotecan in solid tumors

Oct. 31, 2003

Targeted therapy of AML with anti-FLT3 antibody under evaluation

Oct. 30, 2003

Canadian approval for Gleevec for newly diagnosed Ph+ CML

Oct. 30, 2003

Sankyo intensifies development of anticancer drugs

Oct. 30, 2003

New inhibitors of ZAP-70, FAK and/or Syk designed at Novartis

Oct. 30, 2003

EN-3247 fails to prevent oral mucositis in pivotal trial

Oct. 29, 2003

Bay-43-9006 enters pivotal phase III trial in kidney cancer

Oct. 29, 2003

Yamanouchi describes new antitumor agents from Pseudomonas species

Oct. 29, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 27, 2026.
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
Emerging therapeutic strategies for Parkinson’s at ADPD 2026
BioWorld
Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
With improved technologies, biomarkers, failed drugs may come into their own
BioWorld
At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to...